Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

PXL065

Phase 2Small molecule

PXL065 is one of 41 small molecule programs targeting Hepatitis. It is currently in Phase 2.

2

Indications

2

Total Trials

0

Active Trials

40

Competitors

Pipeline

Status by Indication[3][1]

Indication

HepatitisActive, not recruiting

X-Linked AdrenoleukodystrophyActive, not recruiting

HepatitisPhase 2

Active, not recruiting

X-Linked AdrenoleukodystrophyPhase 2

Active, not recruiting

Competition

Competitive Landscape

237 competitors in Hepatitis

#DrugCompanyPhaseTrials

Actos

Cysteine Hydrochloride

Deltasone

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Crestor

PEG-Intron

Aquasol E

NNational Eye Institute (NEI)

Amoxil

GGlobal Antibiotics Research and Development Partnership

Prevnar

Cervarix

Rimonabant

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Hepatitis1 trial

Study of PXL065 in Patients With Nonalcoholic Steatohepatitis (NASH)

Completed·PPoxel SA·Phase 2·NCT04321343·117 enrolled

X-linked adrenoleukodystrophy1 trial

Study to Assess PXL065 in Subjects With Adrenomyeloneuropathy (AMN) Form of X-linked Adrenoleukodystrophy (X-ALD or ALD)

Withdrawn·PPoxel SA·Phase 2·NCT05200104

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for PXL065. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PXL065 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PXL065. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Poxel SA company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: PPoxel SA

Related News